StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) stock

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3085% above fair value
$270.47+3.33 (+1.25%)

Close on Nov 20, 2026Market cap $651.11BP/E 41.0Yield 1.90%

Johnson & Johnson net income

Net income is the profit left for shareholders after every expense, interest and tax.

Johnson & Johnson's net income for the twelve months ending Sep 27, 2026 was $16.10B, down 35.9% year over year. For fiscal 2025 it was $26.80B, up 90.6% from the year before. Over ten years it grew 5.7% a year on average. The highest annual figure on record is $35.15B in fiscal 2023.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 28, 2025$26.80B+90.6%
FY2024Dec 29, 2024$14.07B-60.0%
FY2023Dec 31, 2023$35.15B+95.9%
FY2022Jan 1, 2023$17.94B-14.1%
FY2021Jan 2, 2022$20.88B+41.9%
FY2020Jan 3, 2021$14.71B-2.7%
FY2019Dec 29, 2019$15.12B-1.2%
FY2018Dec 30, 2018$15.30B+1076.7%
FY2017Dec 31, 2017$1.30B-92.1%
FY2016Jan 1, 2017$16.54B+7.3%
FY2015Jan 3, 2016$15.41B-5.6%
FY2014Dec 28, 2014$16.32B+18.0%
FY2013Dec 29, 2013$13.83B+27.4%
FY2012Dec 30, 2012$10.85B+12.2%
FY2011Jan 1, 2012$9.67B-27.5%
FY2010Jan 2, 2011$13.33B–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 27, 2026$210.00M-95.9%
Q2 FY2026Jun 28, 2026$5.53B-0.1%
Q1 FY2026Mar 29, 2026$5.24B-52.4%
Q4 FY2025Dec 28, 2025$5.12B+49.1%
Q3 FY2025Sep 28, 2025$5.15B+91.2%
Q2 FY2025Jun 29, 2025$5.54B+18.2%
Q1 FY2025Mar 30, 2025$11.00B+237.9%
Q4 FY2024Dec 29, 2024$3.43B-15.3%
Q3 FY2024Sep 29, 2024$2.69B-89.6%
Q2 FY2024Jun 30, 2024$4.69B-8.9%
Q1 FY2024Mar 31, 2024$3.26B–
Q4 FY2023Dec 31, 2023$4.05B+15.0%
Q3 FY2023Oct 1, 2023$26.03B+483.8%
Q2 FY2023Jul 2, 2023$5.14B+6.9%
Q1 FY2023Apr 2, 2023-$68.00M-101.3%
Q4 FY2022Jan 1, 2023$3.52B-25.7%
Q3 FY2022Oct 2, 2022$4.46B+21.6%
Q2 FY2022Jul 3, 2022$4.81B-23.3%
Q1 FY2022Apr 3, 2022$5.15B-16.9%
Q4 FY2021Jan 2, 2022$4.74B+172.5%
Q3 FY2021Oct 3, 2021$3.67B+3.2%
Q2 FY2021Jul 4, 2021$6.28B+73.1%
Q1 FY2021Apr 4, 2021$6.20B+6.9%
Q4 FY2020Jan 3, 2021$1.74B-56.7%
Q3 FY2020Sep 27, 2020$3.55B+102.7%
Q2 FY2020Jun 28, 2020$3.63B-35.3%
Q1 FY2020Mar 29, 2020$5.80B+54.6%
Q4 FY2019Dec 29, 2019$4.01B+31.8%
Q3 FY2019Sep 29, 2019$1.75B-55.4%
Q2 FY2019Jun 30, 2019$5.61B+41.8%
Q1 FY2019Mar 31, 2019$3.75B-14.2%
Q4 FY2018Dec 30, 2018$3.04B–
Q3 FY2018Sep 30, 2018$3.93B+4.5%
Q2 FY2018Jul 1, 2018$3.95B+3.3%
Q1 FY2018Apr 1, 2018$4.37B-1.2%
Q4 FY2017Dec 31, 2017-$10.71B-380.9%
Q3 FY2017Oct 1, 2017$3.76B–
Q2 FY2017Jul 2, 2017$3.83B–
Q1 FY2017Apr 2, 2017$4.42B–
Q4 FY2016Jan 1, 2017$3.81B–

More Johnson & Johnson figures

See a number that looks wrong?